Comparison of Postoperative Analgesic Effects of Quadro-iliac Plane Block and Transversus Abdominis Plane Blocks in Inguinal Hernia Surgery

NCT07442188 | Not Yet Recruiting

• 1 other identifier: AEŞH-EK-2026-017
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Inguinal hernia repair is one of the most commonly performed surgical procedures worldwide. Despite being classified as a minor surgical intervention, moderate to severe postoperative pain is reported in approximately 60% of patients. In a subset of these patients, acute postoperative pain may persist and evolve into chronic post-surgical inguinal pain, significantly affecting quality of life. In recent years, beyond the use of systemic intravenous analgesics, ultrasound-guided fascial plane blocks have been increasingly incorporated into multimodal analgesia protocols with the aim of reducing postoperative opioid consumption and improving pain control. However, the current literature does not provide definitive evidence regarding the superiority of one block technique over another in this surgical population. The primary objective of the present study is to compare the analgesic efficacy of the Quadro-iliac Plane Block (QIPB) and the transversus abdominis plane block (TAPB) in patients undergoing inguinal hernia repair.

Conditions

Peripheral Nerve Block; Pain Management; Hernia, Inguinal

Keywords

Quadro Iliac Plane Block; Transversus Abdominis Plane Block

Outcome Measures

Primary Outcomes (1)

• Pain Score

  Pain will be assessed using a visual analog scale from 0 mm (no pain) to 100 mm (worst pain) at rest and when coughing. Pain assessment will be made at 0, 1, 6, 12, 18, and 24 hours after surgery.

  Up to 24 hours

Secondary Outcomes (1)

• Patient Satisfaction

  24th hour

Study Arms (2)

TAPB

ACTIVE COMPARATOR

After the patients were placed under observation, positioned in the supine position, and appropriate area sterilization was performed, TAPB was administered to the patients with 30 ml of 0.25% bupivacaine under ultrasound guidance.

Procedure: TAPB

QIPB

ACTIVE COMPARATOR

After the patients were placed under observation, positioned in the lateral decubitus position, and appropriate area sterilization was performed, QIPB was administered to the patients with 30 ml of 0.25% bupivacaine under ultrasound guidance.

Procedure: QIPB

Interventions

TAPB PROCEDURE

Patients will undergo TAPB procedure using 30 ml of 0.25% bupivacaine under ultrasound guidance.

TAPB

QIPB PROCEDURE

Patients will undergo QIPB procedure using 30 ml of 0.25% bupivacaine under ultrasound guidance.

QIPB

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients aged between 18 and 65 years
• Patients with an American Society of Anesthesiologists (ASA) physical status classification of I-III.
• Patients with a body mass index (BMI) between 18 and 30 kg/m².
• Patients scheduled to undergo unilateral inguinal hernia repair under general anesthesia in the operating room.

You may not qualify if:

• Patients younger than 18 years or older than 65 years.
• Patients with an ASA physical status classification of IV or higher.
• Patients with advanced comorbidities.
• Patients with a history of bleeding diathesis.
• Patients with infection at the site of the planned procedure.
• Patients with a BMI below 18 kg/m² or above 30 kg/m².

Sponsors & Collaborators

• Ankara Etlik City Hospital: lead

Study Sites (1)

Ankara Etlik City Hospital

Ankara, Yenimahalle\Ankara, 06170, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Agnosia; Hernia, Inguinal

Interventions

1,3-bis(4-amidinophenoxy)-2-(4-amidinophenoxymethyl)ethylpropane

Condition Hierarchy (Ancestors)

Perceptual Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Hernia, Abdominal; Hernia; Pathological Conditions, Anatomical

Central Study Contacts

Ibrahim Topcu, MD

CONTACT

+905437860316; ibrahimtpc78@gmail.com

Musa Zengin, Associate Professor

CONTACT

+905307716235; musazengin@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: February 24, 2026
• First Posted: March 2, 2026
• Study Start: March 1, 2026
• Primary Completion (Estimated): October 5, 2026
• Study Completion (Estimated): October 19, 2026
• Last Updated: March 6, 2026

Record last verified: 2026-03

Locations

TU (1)